{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:28:43Z","timestamp":1778048923063,"version":"3.51.4"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"28","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1097\/md.0000000000007151","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T14:40:11Z","timestamp":1499784011000},"page":"e7151","source":"Crossref","is-referenced-by-count":24,"title":["Alemtuzumab versus antithymocyte globulin induction therapies in kidney transplantation patients"],"prefix":"10.1097","volume":"96","author":[{"given":"Jianming","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-3-20210226","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0272-6386(03)00916-8","article-title":"A population-based study of the incidence and outcomes of diagnosed chronic kidney disease","volume":"42","author":"Drey","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R2-3-20210226","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N Engl J Med"},{"key":"R3-3-20210226","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.1996.307","article-title":"A study of the quality of life and cost-utility of renal transplantation","volume":"50","author":"Laupacis","year":"1996","journal-title":"Kidney Int"},{"issue":"Suppl 3","key":"R4-3-20210226","first-page":"S1","article-title":"Am J T","volume":"9","year":"2009","journal-title":"ransplant"},{"key":"R7-3-20210226","doi-asserted-by":"crossref","first-page":"957549","DOI":"10.1155\/2010\/957549","article-title":"Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: three or four days?","volume":"2010","author":"Hardinger","year":"2010","journal-title":"J Transplant"},{"key":"R8-3-20210226","first-page":"39","article-title":"Antibody induction therapy in renal transplant patients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review","volume":"19","author":"Nashan","year":"2005","journal-title":"Bio Drugs"},{"key":"R9-3-20210226","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1111\/j.1600-6143.2005.01067.x","article-title":"Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction\u2014long-term results","volume":"5","author":"Kaufman","year":"2005","journal-title":"Am J Transplant"},{"key":"R10-3-20210226","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1600-6143.2008.02273.x","article-title":"Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial","volume":"8","author":"Margreiter","year":"2008","journal-title":"Am J Transplant"},{"key":"R11-3-20210226","first-page":"514","article-title":"Adding thymoglobuline to the conventional immunosuppressant regimen in kidney transplantation: a cost-benefit analysis","volume":"3","author":"Oliaei","year":"2012","journal-title":"Caspian J Intern Med"},{"key":"R12-3-20210226","doi-asserted-by":"crossref","first-page":"c65","DOI":"10.1159\/000086224","article-title":"Cyclosporine prolongs delayed graft function in kidney transplantation: are rabbit anti-human thymocyte globulins the answer?","volume":"101","author":"Cravedi","year":"2005","journal-title":"Nephron Clin Pract"},{"key":"R13-3-20210226","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1009546","article-title":"Alemtuzumab induction in renal transplantation","volume":"364","author":"Hanaway","year":"2011","journal-title":"N Engl J Med"},{"key":"R14-3-20210226","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R15-3-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R16-3-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R17-3-20210226","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0272989X05282643","article-title":"The interpretation of random-effects meta-analysis in decision models","volume":"25","author":"Ades","year":"2005","journal-title":"Med Decis Making"},{"key":"R19-3-20210226","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R21-3-20210226","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R22-3-20210226","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R23-3-20210226","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1097\/01.tp.0000263344.53000.a1","article-title":"Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation","volume":"83","author":"Thomas","year":"2007","journal-title":"Transplantation"},{"key":"R24-3-20210226","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1016\/j.transproceed.2010.08.045","article-title":"Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation","volume":"42","author":"Ciancio","year":"2010","journal-title":"Transplant Proc"},{"key":"R25-3-20210226","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1399-0012.2007.00774.x","article-title":"A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up","volume":"22","author":"Ciancio","year":"2008","journal-title":"Clin Transplant"},{"key":"R26-3-20210226","first-page":"664","article-title":"Alemtuzumab induction therapy in highly sensitized kidney transplant recipients","volume":"124","author":"Lu","year":"2011","journal-title":"Chin Med J (Engl"},{"key":"R27-3-20210226","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1097\/TP.0b013e3181b4acfb","article-title":"A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation","volume":"88","author":"Farney","year":"2009","journal-title":"Transplantation"},{"key":"R28-3-20210226","first-page":"89","article-title":"A nonparametric \u201ctrim and fill\u201d method of accounting for publication bias in meta-analysis","volume":"95","author":"Duval","year":"2000","journal-title":"J Am Stat Assoc"},{"key":"R29-3-20210226","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/TP.0b013e318257ad41","article-title":"Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis","volume":"93","author":"Morgan","year":"2012","journal-title":"Transplantation"},{"key":"R30-3-20210226","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.trim.2012.08.006","article-title":"Alemtuzumab induction in renal transplantation: a meta-analysis and systemic review","volume":"27","author":"Zhang","year":"2012","journal-title":"Transpl Immunol"},{"key":"R31-3-20210226","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1016\/j.transproceed.2012.05.085","article-title":"The efficacy and safety of alemtuzumab and daclizumab versus antithymocyte globulin during organ transplantation: a meta-analysis","volume":"44","author":"Hao","year":"2012","journal-title":"Transplant Proc"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000007151","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,30]],"date-time":"2022-07-30T19:28:19Z","timestamp":1659209299000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201707140-00003"}},"subtitle":["A systematic review and meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":27,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000007151","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}